Nyxoah S.A. (NYXH)
USD 6.12
(1.75%)
USD 6.12
(1.75%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.34 Million EUR | 40.99% |
| 2022 | 3.08 Million EUR | 261.97% |
| 2021 | 852 Thousand EUR | 1134.78% |
| 2020 | 69 Thousand EUR | 0.0% |
| 2019 | - EUR | 0.0% |
| 2018 | - EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.22 Million EUR | -33.06% |
| 2024 Q2 | 771 Thousand EUR | -36.86% |
| 2023 Q1 | 441 Thousand EUR | -66.26% |
| 2023 Q3 | 976 Thousand EUR | -11.83% |
| 2023 Q2 | 1.1 Million EUR | 151.02% |
| 2023 FY | 4.34 Million EUR | 40.99% |
| 2023 Q4 | 1.82 Million EUR | 86.89% |
| 2022 Q2 | 935 Thousand EUR | 41.67% |
| 2022 Q1 | 660 Thousand EUR | 123.73% |
| 2022 FY | 3.08 Million EUR | 261.97% |
| 2022 Q3 | 182 Thousand EUR | -80.53% |
| 2022 Q4 | 1.3 Million EUR | 618.13% |
| 2021 Q2 | 170 Thousand EUR | -8.11% |
| 2021 Q3 | 203 Thousand EUR | 19.41% |
| 2021 FY | 852 Thousand EUR | 1134.78% |
| 2021 Q4 | 295 Thousand EUR | 45.32% |
| 2021 Q1 | 185 Thousand EUR | 436.23% |
| 2020 Q3 | 34.5 Thousand EUR | 0.0% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 69 Thousand EUR | 0.0% |
| 2020 Q4 | 34.5 Thousand EUR | 0.0% |
| 2020 Q2 | - EUR | 0.0% |
| 2019 Q3 | - EUR | 0.0% |
| 2019 Q4 | - EUR | 0.0% |
| 2019 Q2 | - EUR | 0.0% |
| 2019 FY | - EUR | 0.0% |
| 2019 Q1 | - EUR | 0.0% |
| 2018 FY | - EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 96.63 Million USD | 95.501% |
| AngioDynamics, Inc. | 303.91 Million USD | 98.569% |
| AtriCure, Inc. | 399.24 Million USD | 98.911% |
| Avinger, Inc. | 7.65 Million USD | 43.178% |
| Azenta, Inc. | 665.07 Million USD | 99.346% |
| BioLife Solutions, Inc. | 143.27 Million USD | 96.965% |
| The Cooper Companies, Inc. | 3.59 Billion USD | 99.879% |
| Daxor Corporation | 1.28 Million USD | -239.551% |
| Ekso Bionics Holdings, Inc. | 18.27 Million USD | 76.213% |
| Femasys Inc. | 1.07 Million USD | -305.608% |
| GlucoTrack, Inc. | - USD | -Infinity% |
| Harvard Bioscience, Inc. | 112.25 Million USD | 96.127% |
| Hologic, Inc. | 4.03 Billion USD | 99.892% |
| ICU Medical, Inc. | 2.25 Billion USD | 99.808% |
| Intuitive Surgical, Inc. | 7.12 Billion USD | 99.939% |
| KORU Medical Systems, Inc. | 28.51 Million USD | 84.753% |
| LeMaitre Vascular, Inc. | 193.48 Million USD | 97.753% |
| Innovative Eyewear, Inc. | 1.15 Million USD | -277.274% |
| Innovative Eyewear, Inc. | 1.15 Million USD | -277.274% |
| Masimo Corporation | 2.04 Billion USD | 99.788% |
| Microbot Medical Inc. | - USD | -Infinity% |
| Meihua International Medical Technologies Co., Ltd. | 97.09 Million USD | 95.522% |
| Merit Medical Systems, Inc. | 1.25 Billion USD | 99.654% |
| Nephros, Inc. | 14.23 Million USD | 69.462% |
| NovoCure Limited | 509.33 Million USD | 99.146% |
| NEXGEL, Inc. | 4.08 Million USD | -6.334% |
| NEXGEL, Inc. | 4.08 Million USD | -6.334% |
| Singular Genomics Systems, Inc. | 2.91 Million USD | -49.364% |
| OraSure Technologies, Inc. | 405.47 Million USD | 98.928% |
| Pro-Dex, Inc. | 53.84 Million USD | 91.925% |
| Pulse Biosciences, Inc. | - USD | -Infinity% |
| Predictive Oncology Inc. | 1.78 Million USD | -144.257% |
| Precision Optics Corporation, Inc. | 19.1 Million USD | 77.241% |
| QuidelOrtho Corporation | 2.99 Billion USD | 99.855% |
| Repligen Corporation | 638.76 Million USD | 99.319% |
| Sanara MedTech Inc. | 64.98 Million USD | 93.31% |
| STAAR Surgical Company | 322.41 Million USD | 98.651% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 50.22 Million USD | 91.343% |
| DENTSPLY SIRONA Inc. | 3.96 Billion USD | 99.89% |
| Jin Medical International Ltd. | 19.82 Million USD | 78.064% |